Humankind Investments LLC Raises Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Humankind Investments LLC boosted its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 4.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 6,571 shares of the medical equipment provider’s stock after acquiring an additional 262 shares during the quarter. Humankind Investments LLC’s holdings in Zimmer Biomet were worth $694,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of the stock. Dodge & Cox boosted its holdings in Zimmer Biomet by 12.0% during the fourth quarter. Dodge & Cox now owns 19,118,436 shares of the medical equipment provider’s stock worth $2,019,480,000 after buying an additional 2,044,645 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Zimmer Biomet by 1.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 14,760,444 shares of the medical equipment provider’s stock worth $1,559,147,000 after acquiring an additional 176,337 shares in the last quarter. Van ECK Associates Corp grew its position in shares of Zimmer Biomet by 5.9% during the 4th quarter. Van ECK Associates Corp now owns 3,955,449 shares of the medical equipment provider’s stock valued at $417,814,000 after acquiring an additional 218,688 shares during the period. Franklin Resources Inc. increased its stake in shares of Zimmer Biomet by 398.7% in the 4th quarter. Franklin Resources Inc. now owns 3,497,764 shares of the medical equipment provider’s stock valued at $369,469,000 after purchasing an additional 2,796,372 shares in the last quarter. Finally, Northern Trust Corp raised its holdings in Zimmer Biomet by 7.6% in the 4th quarter. Northern Trust Corp now owns 2,370,224 shares of the medical equipment provider’s stock worth $250,367,000 after purchasing an additional 167,435 shares during the period. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Insider Activity at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,443 shares of Zimmer Biomet stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the transaction, the senior vice president now owns 8,768 shares in the company, valued at approximately $915,379.20. This trade represents a 14.13 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 1.39% of the stock is currently owned by company insiders.

Zimmer Biomet Price Performance

Zimmer Biomet stock opened at $95.22 on Friday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91. The company has a market capitalization of $18.84 billion, a price-to-earnings ratio of 21.40, a price-to-earnings-growth ratio of 1.95 and a beta of 0.78. The company’s 50 day simple moving average is $104.43 and its 200-day simple moving average is $106.12. Zimmer Biomet Holdings, Inc. has a 1 year low of $89.92 and a 1 year high of $122.25.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.77 by $0.04. The company had revenue of $1.91 billion for the quarter, compared to analyst estimates of $1.89 billion. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. The business’s revenue for the quarter was up 1.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.94 earnings per share. As a group, equities research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st were paid a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 1.01%. The ex-dividend date of this dividend was Monday, March 31st. Zimmer Biomet’s payout ratio is currently 21.24%.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. JMP Securities cut their price objective on Zimmer Biomet from $140.00 to $125.00 and set a “market outperform” rating for the company in a research report on Wednesday. BTIG Research reaffirmed a “buy” rating on shares of Zimmer Biomet in a report on Monday, April 14th. Wells Fargo & Company cut their target price on shares of Zimmer Biomet from $113.00 to $98.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 6th. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a research note on Friday, February 7th. Finally, Robert W. Baird cut their price objective on Zimmer Biomet from $130.00 to $115.00 and set an “outperform” rating for the company in a research note on Tuesday, May 6th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $114.15.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.